NCT05064085View on ClinicalTrials.gov

Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

September 9, 2024

Study Completion Date

September 30, 2026

Conditions
Hormone Receptor-positive Breast Cancer
Interventions
DRUG

Cemiplimab

Participants will be given Cemiplimab 350 mg IV day 1 every 21 days

DRUG

Capecitabine

Participants will take Capecitabine at 2 dose levels: 800 mg/m\^2 and 1000 mg/m\^2 by mouth twice daily 14 days on, 7 days off starting on day 3 every 21 days.

Trial Locations (1)

33612

Moffitt Cancer Center, Tampa

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER